Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.
Thomas E WilliamsKatherine P HoldsworthJennifer M NicholasE Ann YehTheodora KatsanouliHenrietta WellingtonAmanda HeslegraveHenrik ZetterbergChris FrostJeremy ChatawayPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
This study provides class I evidence that simvastatin treatment does not have a large impact on either serum NfL or NfH, as quantified in this study, in SPMS.